These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20678072)

  • 1. Targeting heat shock proteins in tauopathies.
    Deture M; Hicks C; Petrucelli L
    Curr Alzheimer Res; 2010 Dec; 7(8):677-84. PubMed ID: 20678072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N; Suárez-Calvet M; Lleó A
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology.
    Dabir DV; Trojanowski JQ; Richter-Landsberg C; Lee VM; Forman MS
    Am J Pathol; 2004 Jan; 164(1):155-66. PubMed ID: 14695329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp70 alters tau function and aggregation in an isoform specific manner.
    Voss K; Combs B; Patterson KR; Binder LI; Gamblin TC
    Biochemistry; 2012 Jan; 51(4):888-98. PubMed ID: 22236337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport.
    Patterson KR; Ward SM; Combs B; Voss K; Kanaan NM; Morfini G; Brady ST; Gamblin TC; Binder LI
    Biochemistry; 2011 Nov; 50(47):10300-10. PubMed ID: 22039833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraneuronal accumulation of misfolded tau protein induces overexpression of Hsp27 in activated astrocytes.
    Filipcik P; Cente M; Zilka N; Smolek T; Hanes J; Kucerak J; Opattova A; Kovacech B; Novak M
    Biochim Biophys Acta; 2015 Jul; 1852(7):1219-29. PubMed ID: 25772164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.
    Miyata Y; Koren J; Kiray J; Dickey CA; Gestwicki JE
    Future Med Chem; 2011 Sep; 3(12):1523-37. PubMed ID: 21882945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.
    Luo W; Dou F; Rodina A; Chip S; Kim J; Zhao Q; Moulick K; Aguirre J; Wu N; Greengard P; Chiosis G
    Proc Natl Acad Sci U S A; 2007 May; 104(22):9511-6. PubMed ID: 17517623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Strategies for Restoring Tau Homeostasis.
    Young ZT; Mok SA; Gestwicki JE
    Cold Spring Harb Perspect Med; 2018 Jan; 8(1):. PubMed ID: 28159830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DnaJC7 binds natively folded structural elements in tau to inhibit amyloid formation.
    Hou Z; Wydorski PM; Perez VA; Mendoza-Oliva A; Ryder BD; Mirbaha H; Kashmer O; Joachimiak LA
    Nat Commun; 2021 Sep; 12(1):5338. PubMed ID: 34504072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp40s play complementary roles in the prevention of tau amyloid formation.
    Irwin R; Faust O; Petrovic I; Wolf SG; Hofmann H; Rosenzweig R
    Elife; 2021 Aug; 10():. PubMed ID: 34369377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated tau and the neurodegenerative foldopathies.
    Kosik KS; Shimura H
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):298-310. PubMed ID: 15615647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stress proteins in Alzheimer's disease.
    Smith RC; Rosen KM; Pola R; Magrané J
    Int J Hyperthermia; 2005 Aug; 21(5):421-31. PubMed ID: 16048839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further understanding of tau phosphorylation: implications for therapy.
    Medina M; Avila J
    Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular factors modulating the mechanism of tau protein aggregation.
    Fontaine SN; Sabbagh JJ; Baker J; Martinez-Licha CR; Darling A; Dickey CA
    Cell Mol Life Sci; 2015 May; 72(10):1863-79. PubMed ID: 25666877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.
    Salminen A; Ojala J; Kaarniranta K; Hiltunen M; Soininen H
    Prog Neurobiol; 2011 Jan; 93(1):99-110. PubMed ID: 21056617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The proceeding of drug development based on the propagation of tau protein].
    Suzuki G; Hasegawa M
    Nihon Rinsho; 2016 Mar; 74(3):432-7. PubMed ID: 27025082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chaperones increase association of tau protein with microtubules.
    Dou F; Netzer WJ; Tanemura K; Li F; Hartl FU; Takashima A; Gouras GK; Greengard P; Xu H
    Proc Natl Acad Sci U S A; 2003 Jan; 100(2):721-6. PubMed ID: 12522269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau.
    Xie C; Soeda Y; Shinzaki Y; In Y; Tomoo K; Ihara Y; Miyasaka T
    J Neurochem; 2015 Oct; 135(1):19-26. PubMed ID: 26134402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.